Itraconazole versus ketaconazole in the treatment of oral and oesophageal candidosis in patients infected with HIV. NLM AIDSLINE Important note: Information in this article was accurate in 1992. The state of the art may have changed since the publication date.

Click here to return to AIDSLINE main menu
DonateNow
Print this Article


Itraconazole versus ketaconazole in the treatment of oral and oesophageal candidosis in patients infected with HIV.

AIDS. 1991 Nov;5(11):1367-71. Unique Identifier : AIDSLINE MED/92118267
Smith DE; Midgley J; Allan M; Connolly GM; Gazzard BG; AIDS Unit, St. Stephens Clinic, London, UK.

Abstract: To determine the efficacy and toxicity of two systemically active antifungal agents in the treatment of buccal and oesophageal candidiasis 111 HIV-infected patients with microscopically-confirmed candidiasis were randomized to receive either 200 mg itraconazole once a day or 200 mg ketoconazole twice a day for 28 days in a double blind study. After 1 week of treatment, 75 and 82% of the patients on itraconazole and ketoconazole, respectively, had responded clinically. After 4 weeks of treatment, this had risen to 93% in each group. One patient discontinued itraconozole because of toxicity (rash), five patients discontinued ketaconazole (two nausea, two hepatotoxicity and one rash). Despite successful clinical and mycological clearance, 80% patients had a further episode of candidosis within the next 3 months.
Keywords: Antifungal Agents/ADVERSE EFFECTS/THERAPEUTIC USE Candidiasis/*COMPLICATIONS/*DRUG THERAPY Candidiasis, Oral/COMPLICATIONS/DRUG THERAPY Comparative Study Double-Blind Method Esophageal Diseases/COMPLICATIONS/DRUG THERAPY Female Human HIV Infections/*COMPLICATIONS Ketoconazole/*ANALOGS & DERIVATIVES/ADVERSE EFFECTS/*THERAPEUTIC USE Male Opportunistic Infections/*COMPLICATIONS/*DRUG THERAPY Recurrence Support, Non-U.S. Gov't CLINICAL TRIAL JOURNAL ARTICLE RANDOMIZED CONTROLLED TRIALKWDantifungalagents/adverseeffects/therapeuticusecandidiasis/KWDcomplications/KWDdrugtherapycandidiasis,oral/complications/drugtherapycomparativestudydouble-blindmethodesophagealdiseases/complications/drugtherapyfemalehumanhivinfections/KWDcomplicationsketoconazole/KWDanalogs&derivatives/adverseeffects/KWDtherapeuticusemaleopportunisticinfections/KWDcomplications/KWDdrugtherapyrecurrencesupport,non-uKWDsKWDgov'tclinicaltrialjournalarticlerandomizedcontrolledtrial
920430
M9240360

Copyright © 1992 - National Library of Medicine. Reproduced under license with the National Library of Medicine, Bethesda, MD.

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1992. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1992. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .